Literature DB >> 30737575

Intravenous immunoglobulins as first-line therapy for IgLON5 encephalopathy.

K Logmin1, A S Moldovan1,2, S Elben1,2, A Schnitzler1,2, S J Groiss3,4.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2019        PMID： 30737575     DOI： 10.1007/s00415-019-09221-3

Source DB:  PubMed          Journal:  J Neurol        ISSN： 0340-5354            Impact factor:   4.849


× No keyword cloud information.
  8 in total

1.  Treatment and prognostic factors for long-term outcome in patients with anti-NMDA receptor encephalitis: an observational cohort study.

Authors:  Maarten J Titulaer; Lindsey McCracken; Iñigo Gabilondo; Thaís Armangué; Carol Glaser; Takahiro Iizuka; Lawrence S Honig; Susanne M Benseler; Izumi Kawachi; Eugenia Martinez-Hernandez; Esther Aguilar; Núria Gresa-Arribas; Nicole Ryan-Florance; Abiguei Torrents; Albert Saiz; Myrna R Rosenfeld; Rita Balice-Gordon; Francesc Graus; Josep Dalmau
Journal:  Lancet Neurol       Date:  2013-01-03       Impact factor: 44.182

2.  Clinical manifestations of the anti-IgLON5 disease.

Authors:  Carles Gaig; Francesc Graus; Yarko Compta; Birgit Högl; Luis Bataller; Norbert Brüggemann; Caroline Giordana; Anna Heidbreder; Katya Kotschet; Jan Lewerenz; Stefan Macher; Maria J Martí; Teresa Montojo; Jesus Pérez-Pérez; Inmaculada Puertas; Caspar Seitz; Mateus Simabukuro; Nieves Téllez; Klaus-Peter Wandinger; Alex Iranzo; Guadalupe Ercilla; Lidia Sabater; Joan Santamaría; Josep Dalmau
Journal:  Neurology       Date:  2017-04-05       Impact factor: 9.910

3.  Chorea and parkinsonism associated with autoantibodies to IgLON5 and responsive to immunotherapy.

Authors:  Ren Haitao; Yang Yingmai; Huang Yan; Han Fei; Lv Xia; Hao Honglin; Liu Chaiyan; Winfried Stöcker; Cui Liying; Guan Hongzhi
Journal:  J Neuroimmunol       Date:  2016-09-24       Impact factor: 3.478

4.  A novel non-rapid-eye movement and rapid-eye-movement parasomnia with sleep breathing disorder associated with antibodies to IgLON5: a case series, characterisation of the antigen, and post-mortem study.

Authors:  Lidia Sabater; Carles Gaig; Ellen Gelpi; Luis Bataller; Jan Lewerenz; Estefanía Torres-Vega; Angeles Contreras; Bruno Giometto; Yaroslau Compta; Cristina Embid; Isabel Vilaseca; Alex Iranzo; Joan Santamaría; Josep Dalmau; Francesc Graus
Journal:  Lancet Neurol       Date:  2014-04-03       Impact factor: 44.182

5.  IgLON5 disease responsive to immunotherapy.

Authors:  Michael Bonello; Anu Jacob; Mark A Ellul; Erandi Barker; Robert Parker; Samantha Jefferson; Sundus Alusi
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-08-07

6.  Faciobrachial dystonic seizures: the influence of immunotherapy on seizure control and prevention of cognitive impairment in a broadening phenotype.

Authors:  Sarosh R Irani; Charlotte J Stagg; Jonathan M Schott; Clive R Rosenthal; Susanne A Schneider; Philippa Pettingill; Rosemary Pettingill; Patrick Waters; Adam Thomas; Natalie L Voets; Manuel J Cardoso; David M Cash; Emily N Manning; Bethan Lang; Shelagh J M Smith; Angela Vincent; Michael R Johnson
Journal:  Brain       Date:  2013-09-06       Impact factor: 13.501

7.  Sleep disorder, chorea, and dementia associated with IgLON5 antibodies.

Authors:  Mateus M Simabukuro; Lidia Sabater; Tarso Adoni; Rubens Gisbert Cury; Mônica Santoro Haddad; Camila Hobi Moreira; Luana Oliveira; Mateus Boaventura; Rosana Cardoso Alves; Leticia Azevedo Soster; Ricardo Nitrini; Carles Gaig; Joan Santamaria; Josep Dalmau; Francesc Graus
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-07-23

8.  IgLON5 antibody: Neurological accompaniments and outcomes in 20 patients.

Authors:  Josephe A Honorat; Lars Komorowski; Keith A Josephs; Kai Fechner; Erik K St Louis; Shannon R Hinson; Sabine Lederer; Neeraj Kumar; Avi Gadoth; Vanda A Lennon; Sean J Pittock; Andrew McKeon
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2017-07-18
  8 in total
  4 in total

1.  Frequency and Characterization of Movement Disorders in Anti-IgLON5 Disease.

Authors:  Carles Gaig; Yaroslau Compta; Anna Heidbreder; Maria J Marti; Maarten J Titulaer; Yvette Crijnen; Birgit Högl; Jan Lewerenz; María Elena Erro; Juan Carlos Garcia-Monco; Pasquale Nigro; Nicola Tambasco; Maja Patalong-Ogiewa; Marcus Erdler; Stefan Macher; Evelyn Berger-Sieczkowski; Romana Höftberger; Christian Geis; Markus Hutterer; Angela Milán-Tomás; Antonio Martin-Bastida; Lydia Lopez Manzanares; Sonia Quintas; Günter U Höglinger; Nora Möhn; Florian Schoeberl; Franziska S Thaler; Gian Maria Asioli; Federica Provini; Giuseppe Plazzi; Koldo Berganzo; Morten Blaabjerg; Norbert Brüggemann; Tarsis Farias; Chen Fei Ng; Caroline Giordana; Alejandro Herrero-San Martín; Lucio Huebra; Katya Kotschet; Herburg Liendl; Teresa Montojo; Carlos Morata; Jesus Perez Perez; Inmaculada Puertas; Thomas Seifert-Held; Caspar Seitz; Mateus Mistieri Simabukuro; Nieves Tellez; Javier Villacieros-Álvarez; Barbara Willekens; Lidia Sabater; Alex Iranzo; Joan Santamaria Cano; Josep Dalmau; Francesc Graus
Journal:  Neurology       Date:  2021-08-11       Impact factor: 11.800

2.  Figural Memory Impairment in Conjunction With Neuropsychiatric Symptoms in IgLON5 Antibody-Associated Autoimmune Encephalitis.

Authors:  Niels Hansen; Sina Hirschel; Winfried Stöcker; Anja Manig; Hannah Sönne Falk; Marielle Ernst; Ruth Vukovich; Inga Zerr; Jens Wiltfang; Claudia Bartels
Journal:  Front Psychiatry       Date:  2020-07-03       Impact factor: 4.157

3.  Anti-IgLON5 Disease: A Case With 11-Year Clinical Course and Review of the Literature.

Authors:  Mette Scheller Nissen; Morten Blaabjerg
Journal:  Front Neurol       Date:  2019-10-02       Impact factor: 4.003

Review 4.  Anti-IgLON5 Disease - The Current State of Knowledge and Further Perspectives.

Authors:  Natalia Madetko; Weronika Marzec; Agata Kowalska; Dominika Przewodowska; Piotr Alster; Dariusz Koziorowski
Journal:  Front Immunol       Date:  2022-03-01       Impact factor: 7.561
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.